Tachyon Receives Funding from CIRM for a Phase I Clinical Study of TACH101, a First-in-Class KDM4 Inhibitor, in Patients with Advanced Solid Tumors

Tachyon Therapeutics, Inc. announced that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $7.1 million grant to support a Phase I clinical study of TACH101 in patients with advanced solid tumors.